Tardive Dyskinesia (TD) is an involuntary movement disorder characterized by repetitive and uncontrollable movements, commonly associated with prolonged use of antipsychotics. It is estimated that up to 30 percent of people receiving prolonged treatment with antipsychotics may develop TD. TD can impact patients’ social, emotional, and physical well-being. However, assessment and management can be challenging due to variable onset of symptoms, fluctuation in frequency and amplitude and patient hesitance to discuss signs and symptoms. During this webinar Amber Hoberg, Psychiatric Mental Health Nurse Practitioner, reviews the clinical manifestations of TD, consequences for patients, and potential management and treatment options. Gavin Clingham, Director of Public Policy at the Alliance for Patient Access, will discuss key policy and regulatory considerations when screening and treating this disorder.
Understand the clinical manifestations and symptoms of TD.
Recognize the impact that TD can have on patients’ health, wellbeing, and daily functioning.
Identify assessment approaches through the Abnormal Involuntary Movement Scale (AIMS).
Review treatment options available to patients experiencing TD.